Global Antisense and RNAi Therapeutics Treatment Market, By Indication (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases and Others), Technology (RNA Interference, Antisense RNA), Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-Dermal, Intraperitoneal, Topical, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Industry Trends and Forecast to 2029
Market Analysis and Insights
Antisense and RNAi therapeutics are two of the most popular approaches to disease treatment. Antisense drugs show promise due to their ability to modulate gene expression, improve cell differentiation processes, and prevent tumour formation, among other advantages. Furthermore, several therapeutic applications based on RNA Interference (RNAi) have been developed, which can be used as a weapon against viruses that cause infections such as hepatitis C virus (HCV), Dengue fever, and others.
- The rising prevalence of genetic diseases, neurological disorders, and advancements in the biotechnological sector are driving the growth of this market. Data Bridge Market Research analyses that the Antisense and RNAi Therapeutics treatment market will grow at a CAGR of 13.00% during the forecast period of 2022 to 2029.
Antisense and RNAi Therapeutics Treatment Market Dynamics
Drivers
-
Advancement and adoption of new technologies for the treatment
The advancement of treatment options for target specificity and selectivity is hastening the growth of the antisense and RNAi therapeutics market. The RNA therapeutics market is growing due to the rapid adoption of newer formulations and novel drug delivery methods. Furthermore, the approval and launch of RNA therapeutics is one of the significant factors driving the growth of this market. Furthermore, regulatory authority special designation for novel therapies can consider the key factors driving market growth.High prevalence of genetic conditions
-
Growing numbers of healthcare institutes
Rising clinician awareness of RNAi therapeutics is expected to drive demand for these drugs. Furthermore, an increasing number of healthcare institutes are focusing on this therapy as an alternative treatment option, which will be a key driving factor for the growth of the global clinic's segment during the forecast period.
Furthermore, advancement in medical technology, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the Antisense and RNAi Therapeutics treatment market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counseling will positively impact the Antisense and RNAi Therapeutics treatment market's growth rate. Additionally, high disposable income, rising number of cases of seizures and changing lifestyle will result in the expansion of Antisense and RNAi Therapeutics treatment market.
Opportunities
Antisense and RNAi therapeutics are useful in the treatment of a variety of diseases that target the nucleic acid and affect the cell growth cycle. MiRNA is generating a lot of buzz because of its ability to restore gene expression and correct protein production, influencing industrial progress. Developments involving research into the use of various routes to deliver the desired effect of the candidate moiety prior to its removal from blood are expected to fuel sector growth.
Restraints/Challenges
However, challenges related to drug delivery are expected to stymie growth to some extent. To reduce the effect of restraining factors, delivery technologies that allow for the mitigation of off-target effects and undesirable immunological stimulation must be introduced.
This Antisense and RNAi Therapeutics treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Antisense and RNAi Therapeutics treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Antisense and RNAi Therapeutics treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Covid-19 Impact on Antisense and RNAi Therapeutics Treatment Market
Over the last 18 months, almost every industry in the world has suffered a setback. This is due to significant disruptions in their respective manufacturing and supply-chain operations as a result of various precautionary lockdowns and other restrictions imposed by governing authorities around the world. The same is true for the global market for Antisense and RNAi Therapeutics. Furthermore, consumer demand has subsequently decreased as people are now more focused on eliminating non-essential expenses from their respective budgets as the general economic status of most people has been severely impacted by this outbreak. These factors are expected to weigh on the revenue trajectory of the global Antisense and RNAi Therapeutics market over the forecast period.
Global Antisense and RNAi Therapeutics Treatment Market Scope
The Antisense and RNAi Therapeutics treatment market is segmented on the basis of indication, technology, and route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Oncology
- Cardiovascular Diseases (Cvds)
- Respiratory Disorders
- Neurological Disorders
- Infectious Diseases
On the basis of indication, the antisense and RNAi therapeutics market is segmented into oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases and others.
Technology
- RNA Interference
- Antisense RNA
The technology segment for antisense and RNAi therapeutics market includes RNA Interference, Antisense RNA. The RNA interference segment is further categorized into small interfering RNA (siRNA) and microRNAs (miRNAs).
Route of administration
- Pulmonary Delivery
- Intravenous Injections
- Intra-Dermal
- Intraperitoneal
- Topical
- Others.
Route of administration segment of antisense and RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intra-dermal, intraperitoneal, topical and others.
End Use
- Clinic
- Hospital
- Others
On the basis of end-users, the antisense and RNAi therapeutics treatment market is segmented into clinic, hospital and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The antisense and RNAi therapeutics treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Pipeline Analysis
The pipeline analysis of anticonvulsant drugs includes various pipeline therapies such as Enzon Pharmaceuticals (Santaris Pharma), OncoGenex, University of Texas, Astrazeneca (Ionis Pharmaceuticals), Isarna Therapeutics and INSYS Therapeutics, Inc.
Antisense and RNAi Therapeutics Treatment Market Regional Analysis/Insights
The antisense and RNAi therapeutics treatment market is analysed and market size insights and trends are provided by country, indication, technology, and route of administration, end-users and distribution channel. as referenced above.
The countries covered in the antisense and RNAi therapeutics treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to account for the largest market share for antisense and RNAi therapeutics in the coming years due to an increase in the rate of genetic disorders and the number of FDA-approved drugs. Europe is expected to have bright growth prospects in the coming years due to an increasing number of chronic disease cases, whereas Asia-Pacific is expected to have significant growth due to the focus of various established market players on expanding their presence in this particular region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Antisense and RNAi Therapeutics Treatment Market Share Analysis
The antisense and RNAi therapeutics treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Antisense and RNAi Therapeutics treatment market.
Some of the major players operating in the antisense and RNAi therapeutics treatment market are Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi, Ionis Pharmaceuticals, Silence Therapeutics, Cenix BioScience, Sirnaomics, CureVac AG, BioNTech SE, Arrowhead Pharmaceuticals, Inc, Arbutus Biopharma, Marina Biotech, Inc, among others.
SKU-
